Skip to main content


Our Programs

Our research and therapeutic pipeline are driven by a commitment to addressing the unmet needs of patients affected by central nervous system (CNS) disorders, neurodegenerative diseases, and rare diseases. These are areas where effective treatments are currently lacking, and where patients are in desperate need of innovative solutions.

Program Target Indication Drug Type Discovery Preclinical Clinical Collaboration
BMD-001 Alzheimer’s disease (AD) BDDSTM – ASO (miR-485-3p Antagomir)
Amyotrophic Lateral Sclerosis (ALS) BDDSTM – ASO (miR-485-3p Antagomir)
Parkinson’s disease (PD) BDDSTM – ASO (miR-485-3p Antagomir)
BMD-0131 Frontotemporal Dementia (FTD) BDDSTM – siRNA (Undisclosed)
BMD-0231 PD & Synucleinopathies BDDSTM – siRNA (Undisclosed)
BMD-0311 Epilepsy BDDSTM – ASO (Undisclosed)
BMD-0431 Glaucoma BDDSTM – RNAi (Undisclosed)
BIOK-0031 CNS disease BDDSTM – siRNA (Undisclosed)
BIOK-0221 CNS disease BDDSTM – ASO (Undisclosed)
BDDSTM = Brain Targeting Drug Delivery System
ALS = Amyotrophic lateral sclerosis

Stay Connected